Stock Ratings / Health Care / CTNM / options

GALT (42) AVIR (40) CYPH (40) ARCT (31) ⌘ Pro Terminal →

Contineum Therapeutics Inc. (Class A) (CTNM) Options Positioning, Max Pain & Unusual Sweeps

$9.33 +1.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.35

Contineum Therapeutics Inc. (Class A) (CTNM) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $351.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.34 (+0.16%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTNM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY CTNM SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 24% of 52W Range • RSI-14 at 43 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$13.38-47.1% Next Q

Q2 (-2Q)

Grade D$7.08+17.4% Next Q

Q3 (-1Q)

Grade D$8.31+12.3% Next Q

Current

Grade D-$9.33-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTNM currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.70) and Max Pain ($9.80) forces dealer call-delta covering toward $18.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CTNM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CTNM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTNM)

✓Walkthrough of CTNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.22%📐 HORIZONTAL RANGE

2026-10-30O $9.14H $9.58L $8.93C $9.33VOL 458.6K

RES: $18.54SUP: $5.80SMA50: $12.70SMA200: $13.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTNM Butterfly Map → + Track CTNM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTNM)

Health Care Rank #639 of 1016 ⚔️ GALT vs CTNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTNM vs. GALT, AVIR, CYPH, ARCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Contineum Therapeutics Inc. (Class A) (CTNM) ranks #639 by composite RQD confidence (40/100, grade D-) and #501 by equity capitalization ($351.0M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. GALT currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with CTNM at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTNM ACTIVE Contineum Therapeutics Inc. (Class A)	D-	40/100	—	—	-29.0%	+1.97%	$351.0M	Benchmark Subject
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-ctnm →
AVIR Atea Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+0.94%	$345.7M	/avir-vs-ctnm →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-ctnm →
ARCT Arcturus Therapeutics Holdings Inc.	E	31/100	—	—	-35.0%	+0.66%	$345.3M	/arct-vs-ctnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855175

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$60.0M, operating cash flow of -$55.3M, and free cash flow of -$55.5M (-66.5% YoY). On the balance sheet, CTNM closed FY2025 with $276.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$60.0M	-$55.3M	-$55.5M	$276.6M	—
FY2024 (FY)	2024-12-31	$0	-$42.3M	-$32.8M	-$33.4M	$212.8M	—
FY2023 (FY)	2023-12-31	$50.0M	$22.7M	$19.3M	$19.3M	—	—

3. CTNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $9.33 (+1.97% 1D, market cap $351.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTNM ranks #639 in composite RQD confidence.

How does CTNM compare to GALT and AVIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.0%. By comparison, GALT (Galectin Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $355.8M) and AVIR (Atea Pharmaceuticals Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $345.7M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTNM?

Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $0 in revenue, -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTNM trading relative to its 50-day, 200-day, and 52-week technical levels?

CTNM last traded at $9.33 (+1.97% on volume of 566,935 shares), positioning the stock -26.54% below its 50-day simple moving average ($12.70) and -31.14% below its 200-day simple moving average ($13.55). Across its 52-week range of $6.73 to $17.79, CTNM sits at the 23.5% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.16 to $10.50).